Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

23 trials with published results (40%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 58 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

55%

32 trials in Phase 3/4

Results Transparency

47%

23 of 49 completed with results

Key Signals

23 with results100% success

Data Visualizations

Phase Distribution

55Total
Not Applicable (3)
Early P 1 (4)
P 1 (4)
P 2 (12)
P 3 (25)
P 4 (7)

Trial Status

Completed49
Unknown6
Active Not Recruiting2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 49 completed trials

Clinical Trials (58)

Showing 20 of 20 trials
NCT05766683Phase 1Active Not RecruitingPrimary

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

NCT06585696Phase 3CompletedPrimary

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)

NCT05565950Phase 1CompletedPrimary

AI-09 In Subjects With Glabellar Lines, GL-101

NCT05481931Active Not RecruitingPrimary

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

NCT03985982Phase 3CompletedPrimary

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT06946160Phase 3Completed

A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines

NCT06411002Phase 2CompletedPrimary

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

NCT02677298Phase 3CompletedPrimary

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677805Phase 3CompletedPrimary

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT05146999Phase 3CompletedPrimary

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

NCT05894109Not ApplicableWithdrawn

Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids

NCT05320393Phase 2CompletedPrimary

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

NCT06124794Phase 3CompletedPrimary

The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

NCT05148000Phase 3CompletedPrimary

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

NCT01485601Phase 2CompletedPrimary

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

NCT05277337Phase 4CompletedPrimary

Study Comparing Treatment With Alluzience vs Reconstituted Toxin

NCT05129319Early Phase 1CompletedPrimary

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

NCT05321979Phase 3CompletedPrimary

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

NCT04715048Early Phase 1UnknownPrimary

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

NCT05364580Phase 3CompletedPrimary

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

Scroll to load more

Research Network

Activity Timeline